New Collaborations and Advancements in RNA-Based Drug Development Programs Lead Santaris Pharma to Establish US Operations

Santaris PharmaAppoints Art Levin Ph.D. as President of US Operations and Chief Development Officer

18-Sep-2009 - USA

Santaris Pharma A/S announced it has established operations in the United States. Increasing interest, new collaborations and breakthrough advancements utilizing the Company's proprietary RNA-based Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine led Santaris Pharma A/S to establish US-based operations inSan Diego, California.

To spearhead the US expansion, Santaris Pharma A/S has appointed Arthur A. Levin, PhD, as President of its US operations. In addition, Dr. Levin will hold global responsibility as Vice President and Chief Development Officer of Santaris Pharma A/S.

Dr. Levin has 15 years of experience in RNA-based research and more than 25 years of experience in the pharmaceutical industry. Prior to joining Santaris Pharma A/S, Dr. Levin was Senior Vice President of Drug Development at Isis Pharmaceuticals where he was instrumental in advancing more than a dozen RNA-based antisense drugs from basic research to clinical development.

Other news from the department business & finance

Most read news

More news from our other portals

So close that even
molecules turn red...

Last viewed contents

Personalized cancer therapy with a "mini-tumour" and digital twin

Personalized cancer therapy with a "mini-tumour" and digital twin

CyBio and Macherey-Nagel collaborate to develop applications for automated DNA/RNA preparation

Innovations for Health: When Molecular Spectroscopy Meets Lasers and Photonics - "An all-optical, minimally invasive and label-free diagnostic tool could represent a significant advance in health..."

Innovations for Health: When Molecular Spectroscopy Meets Lasers and Photonics - "An all-optical, minimally invasive and label-free diagnostic tool could represent a significant advance in health..."

HI viruses crack the lock to the cell nucleus - For the first time, researchers have observed how HIV penetrates the nuclear pores to the genome of human immune cells

HI viruses crack the lock to the cell nucleus - For the first time, researchers have observed how HIV penetrates the nuclear pores to the genome of human immune cells

Closure of Astellas CNS research in Edinburgh

Antibody discovered that blocks almost all known HIV variants in neutralization assays - The discovery potentially opens up new perspectives for the prevention and treatment of HIV infections

Antibody discovered that blocks almost all known HIV variants in neutralization assays - The discovery potentially opens up new perspectives for the prevention and treatment of HIV infections

New method for measuring luminescence lifetime offers breakthrough in scientific imaging - Ac­cel­er­at­ing the pace of dis­cov­ery in sci­ence and in­dustry

New method for measuring luminescence lifetime offers breakthrough in scientific imaging - Ac­cel­er­at­ing the pace of dis­cov­ery in sci­ence and in­dustry

Decreasing biodiversity may promote spread of viruses - New insight into the dynamics of infectious disease

Decreasing biodiversity may promote spread of viruses - New insight into the dynamics of infectious disease

Mysthera Therapeutics Launches to Develop First-in-Class Autoimmune Disease Therapies - Seed Capital from Forty51 Ventures to Advance Pipeline of Pan-PIM Kinase Inhibitors

Mysthera Therapeutics Launches to Develop First-in-Class Autoimmune Disease Therapies - Seed Capital from Forty51 Ventures to Advance Pipeline of Pan-PIM Kinase Inhibitors

3D-printed pills with desired drug release – a step upwards in medication - Funny looking pills are not a design gimmick, they can release medication in a desired time regime!

3D-printed pills with desired drug release – a step upwards in medication - Funny looking pills are not a design gimmick, they can release medication in a desired time regime!

Coronavirus SARS-CoV-2 spreads more indoors at low humidity - Indian-German research team recommends at least 40 percent humidity in public buildings

Coronavirus SARS-CoV-2 spreads more indoors at low humidity - Indian-German research team recommends at least 40 percent humidity in public buildings

Chemische Fabrik Dr. Weigert GmbH & Co. KG - Hamburg, Germany

Chemische Fabrik Dr. Weigert GmbH & Co. KG - Hamburg, Germany